Literature DB >> 21466632

Hypertension in diabetes: treatment considerations.

Mariela Glandt1, Zachary T Bloomgarden.   

Abstract

Treatment of blood pressure in the patient with diabetes remains a challenge. While data extrapolated from many trials seemed to imply that lower blood pressures leads to more favorable cardiovascular outcomes, this paper reviews newer trials designed to treat to blood pressure targets below 130/80 mmHg in patients with long term established diabetes, which showed that this goal may prove more harmful than helpful. In clinical practice this may be less relevant due to the fact that less than half of patients are even at the goal of 130/80. The interaction between glucose control and blood pressure control are also discussed, emphasizing the importance of multifactorial treatment.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21466632      PMCID: PMC8673394          DOI: 10.1111/j.1751-7176.2011.00442.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  38 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  Undertreatment of cardiovascular risk factors among persons with diabetes in the United States.

Authors:  Shaista Malik; Victor Lopez; Roland Chen; Wei Wu; Nathan D Wong
Journal:  Diabetes Res Clin Pract       Date:  2006-11-21       Impact factor: 5.602

Review 3.  Influence of antihypertensive therapy on development and progression of diabetic glomerulopathy.

Authors:  S Anderson; B M Brenner
Journal:  Diabetes Care       Date:  1988 Nov-Dec       Impact factor: 19.112

4.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

Authors:  J D Curb; S L Pressel; J A Cutler; P J Savage; W B Applegate; H Black; G Camel; B R Davis; P H Frost; N Gonzalez; G Guthrie; A Oberman; G H Rutan; J Stamler
Journal:  JAMA       Date:  1996-12-18       Impact factor: 56.272

5.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

Review 6.  Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification.

Authors:  C E Mogensen
Journal:  Am J Cardiol       Date:  1998-11-12       Impact factor: 2.778

7.  Long-term follow-up after tight control of blood pressure in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; H Andrew W Neil; David R Matthews
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.

Authors:  Sophia Zoungas; Bastiaan E de Galan; Toshiharu Ninomiya; Diederick Grobbee; Pavel Hamet; Simon Heller; Stephen MacMahon; Michel Marre; Bruce Neal; Anushka Patel; Mark Woodward; John Chalmers; Alan Cass; Paul Glasziou; Stephen Harrap; Liu Lisheng; Guiseppe Mancia; Avinesh Pillai; Neil Poulter; Vlado Perkovic; Florence Travert
Journal:  Diabetes Care       Date:  2009-08-03       Impact factor: 19.112

View more
  3 in total

Review 1.  The selected traditional chinese medicinal formulas for treating diabetic nephropathy: perspective of modern science.

Authors:  Thing-Fong Tzeng; Shorong-Shii Liou; I-Min Liu
Journal:  J Tradit Complement Med       Date:  2013-07

2.  Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.

Authors:  Ina-Maria Rückert; Michaela Schunk; Rolf Holle; Sabine Schipf; Henry Völzke; Alexander Kluttig; Karin-Halina Greiser; Klaus Berger; Grit Müller; Ute Ellert; Hannelore Neuhauser; Wolfgang Rathmann; Teresa Tamayo; Susanne Moebus; Silke Andrich; Christa Meisinger
Journal:  Cardiovasc Diabetol       Date:  2012-05-08       Impact factor: 9.951

Review 3.  Liuwei Dihuang Pills Enhance the Effect of Western Medicine in Treating Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lan Lin; Qiuhong Wang; Yongxin Yi; Shihan Wang; Zonglin Qiu
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-21       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.